Great news. Here's a list of the Conference Call Topics:
Potential investment infusion; Further developments on FDA Pre-IND application #150335 for Escozine as a COVID-19 treatment; Lobbying to the FDA; Update on Dominican Republic controlled double-blind clinical strategy for Escozine as a COVID-19 treatment; Mexico importation and distribution of Escozine, and clinical strategy and preparation for a study on Escozine as a COVID-19 treatment; The Company’s name and stock symbol change status; Changes to the Company’s executive management and corporate control; Additional distribution opportunities; Implementation of new sales and marketing strategies; Collaborative opportunities with large pharmaceutical companies; Change in the Company’s independent auditing firm; Addressing recent concerns from shareholders; $QNTA